Report from the Annual General meeting of IRLAB Therapeutics AB - Seite 2

It was further resolved that remuneration shall be paid to the board's audit committee with SEK 85,000 to the committee's Chair and SEK 50,000 to each of the other members of the Committee, that remuneration shall be paid to the board´s renumeration committee with SEK 50,000 to the committee's Chair and SEK 30,000 to each of the other members of the committee.

It was resolved that fees to the auditor shall be paid in accordance with invoices approved by the company.

Instruction to the nomination committee

The Annual General Meeting resolved, in accordance with the nomination committee's proposal, that the principles that were adopted at the Annual General Meeting 2022, shall continue to apply as the instruction to the nomination committee and that such principles shall continue to apply until further notice.

Pursuant to the instruction, the nomination committee shall consist of four members that shall be appointed by the three largest shareholders or groups of shareholders in the company in terms of voting rights on the last banking day of August together with the Chair of the board of directors.

The instruction to the nomination committee adopted at the Annual General Meeting 2022, is available on the company's website (www.irlab.se).

Guidelines for salary and other compensation to senior management and the remuneration report

No changes had been proposed to the guidelines for remuneration to the senior management (the "Guidelines") (adopted by the Annual General Meeting 2022) why the Guidelines will continue to apply without any changes.

The Guidelines adopted at the Annual General Meeting 2022, are available on the Company's website (www.irlab.se).

It was further resolved to approve the board of directors' remuneration report for 2022. The board of directors' remuneration report for 2022 provides an outline of how the Guidelines have been implemented in 2022. The remuneration report also provides information on the remuneration to the company's CEO and a summary of the company's outstanding incentive programs. There have been no deviations from the procedure for the implementation of the Guidelines and no derogations from the application of the Guidelines in 2022.